U.S. Industrial REITs Stock News

NasdaqGS:VNOM
NasdaqGS:VNOMOil and Gas

Is It Time To Reconsider Viper Energy (VNOM) After Its Recent Share Price Pullback?

Wondering if Viper Energy's current price really reflects its potential value, or if the stock might offer more than the market is giving it credit for right now. The stock closed at US$46.98, with a 21.3% return over the last year and 21.1% year to date, although the past week saw a 4.9% decline and the past month was flat at 0.0%. Recent coverage has focused on Viper Energy's role in the US energy sector and how investors are weighing its income profile against commodity price movements...
NYSE:CWAN
NYSE:CWANSoftware

Clearwater Analytics Holdings (CWAN) Quarterly Loss Challenges Bullish Profitability Narratives

Clearwater Analytics Holdings (CWAN) closed out FY 2025 with Q4 revenue of US$217.5 million and a basic EPS loss of US$0.04, as net income excluding extra items came in at a loss of US$12.1 million. Over recent periods the company has seen quarterly revenue move from US$126.5 million in Q4 FY 2024 to US$217.5 million in Q4 FY 2025, while basic EPS shifted from US$1.85 a share in Q4 FY 2024 to a loss of US$0.04 a share in the latest quarter. This sets up a results season in which investors are...
NYSE:FERG
NYSE:FERGTrade Distributors

Is Ferguson Enterprises (FERG) Still Fairly Priced After Recent Share Price Pullback?

If you are wondering whether Ferguson Enterprises at around US$246.53 is still worth your attention, it helps to start by separating price moves from underlying value. The stock has seen a 7.9% decline over the last 7 days, set against returns of 4.5% over 30 days, 9.6% year to date, 46.3% over 1 year, 78.6% over 3 years and 109.5% over 5 years. This naturally raises questions about how much future strength or risk is already reflected in the price. Recent coverage of Ferguson Enterprises...
NYSE:MNTN
NYSE:MNTNMedia

What MNTN (MNTN)'s Q1 Profit Rebound and QuickFrame AI 3.0 Launch Mean For Shareholders

MNTN, Inc. recently reported first-quarter 2026 results, with sales rising to US$73.67 million and net income improving to US$8.76 million, reversing a net loss a year earlier and lifting basic earnings per share from continuing operations to US$0.12. On the same day, the company launched QuickFrame AI 3.0, expanding its AI-powered creative platform into a full production workflow that lets brands rapidly generate, edit, and publish multi-format video ads across major digital and TV...
NasdaqGS:INSM
NasdaqGS:INSMBiotechs

Insmed (INSM) Q1 2026 Revenue Surge Tests Profitability Narrative

Insmed (INSM) opened Q1 2026 with revenue of US$306 million and a basic EPS loss of US$0.76, while the trailing twelve months show revenue of US$820 million and a basic EPS loss of US$5.70. Over the past reported quarters, revenue has moved from US$93 million in Q1 2025 to US$306 million in Q1 2026, alongside quarterly basic EPS losses ranging between US$0.76 and US$1.75. This keeps the focus squarely on how efficiently new sales translate into narrowing losses. For investors, the story this...
NasdaqGS:AFRM
NasdaqGS:AFRMDiversified Financial

Affirm Holdings (AFRM) Profitability Milestone Tests Bullish Narratives In Q2 2026 Earnings

Affirm Holdings (AFRM) opened its Q2 2026 update with total revenue of US$1.1b and basic EPS of US$0.39, alongside trailing twelve month revenue of US$3.7b and EPS of US$0.86 that put profitability firmly in focus. The company has seen quarterly revenue move from US$866.4m in Q2 2025 to US$1.1b in Q2 2026, while basic EPS shifted from US$0.25 to US$0.39 over the same period. This sets up this print as a key checkpoint on whether margins are starting to scale more consistently. See our full...
NasdaqGM:LUNR
NasdaqGM:LUNRAerospace & Defense

Is It Too Late To Consider Intuitive Machines (LUNR) After Its Recent Lunar Mission Headlines?

Wondering whether Intuitive Machines stock still offers value after its recent volatility, or if you might be turning up late to the story? The stock closed at US$24.11, with a 4.9% decline over the last 7 days, a 6.1% gain over 30 days, a 34.8% return year to date, and a 157.9% return over the past year. Recent headlines around Intuitive Machines have kept the stock in focus, with investors paying closer attention to how its projects translate into long term potential. This context helps...
NasdaqGM:AGNT
NasdaqGM:AGNTReal Estate

A Look At eXp World Holdings (AGNT) Valuation After Adding Veteran Broker Mario J Alvarez Jr

eXp World Holdings (AGNT) recently drew attention after eXp Commercial added veteran broker Mario J Alvarez Jr, whose two decades in commercial real estate align with the company’s effort to grow its investment sales presence. See our latest analysis for eXp World Holdings. At a share price of $6.60, eXp World Holdings has a 30 day share price return of 10.18% and a 7 day gain of 2.48%. However, the year to date share price return of 27.47% and 90 day share price return of 23.79% point to...
NYSE:TSM
NYSE:TSMSemiconductor

Is It Too Late To Consider Taiwan Semiconductor Manufacturing (NYSE:TSM) After Its 1‑Year Surge?

Wondering whether Taiwan Semiconductor Manufacturing stock still offers value after its strong run, or if you might be arriving late to the story? The share price last closed at US$414.15, with returns of 4.6% over 7 days, 19.9% over 30 days, 29.6% year to date, 138.6% over 1 year, 413.9% over 3 years and 306.3% over 5 years. Recent headlines have focused on Taiwan Semiconductor Manufacturing's central role in global chip supply and its position in advanced manufacturing capacity. This...
NYSE:GRND
NYSE:GRNDInteractive Media and Services

Is Grindr (GRND) Offering Value After A 43% One Year Share Price Decline

If you are wondering whether Grindr stock is priced fairly or if the current level still leaves room for value, you need to look past headlines and into the numbers that shape valuation. Over the last month the share price has moved to US$13.81, with returns of 3.3% over 7 days, 12.4% over 30 days and 3.8% year to date, set against a 43.5% loss over the past year and a 124.2% gain over three years. Recent coverage has focused on Grindr as a listed platform business and how investors are...
NYSE:DHR
NYSE:DHRLife Sciences

Masimo Deal Approval Sets Stage For Danaher Growth And Valuation Re‑Rating

Masimo shareholders have officially approved the merger with Danaher (NYSE:DHR). The vote clears a key milestone for the acquisition and allows the deal process to move toward closing. The transaction is expected to expand Danaher's presence in diagnostics and medical technology once remaining conditions are met. For investors watching NYSE:DHR, this approval matters because it comes at a time when diagnostics, patient monitoring and broader medical technology are central to hospital and...
NasdaqGS:APLS
NasdaqGS:APLSBiotechs

Is It Too Late To Consider Apellis Pharmaceuticals (APLS) After Its 130% One Year Surge?

If you are trying to figure out whether Apellis Pharmaceuticals is attractively priced today, it helps to start with how the current market value lines up against different ways of estimating fair value. The stock last closed at US$41.01, with returns of 0.1% over 7 days, 0.8% over 30 days, 58.6% year to date and 130.3% over the past year, alongside 3 year and 5 year returns of 53.7% decline and 10.1% decline respectively. This gives a mixed picture for anyone thinking about entry or exit...
NYSE:VST
NYSE:VSTRenewable Energy

Vistra (VST) Margin Fall To 4.2% Challenges Bullish Earnings Growth Narrative

Vistra (VST) has wrapped up FY 2025 with fourth quarter revenue of US$4.6b, Basic EPS of US$0.55 and net income of US$185m, rounding out a trailing twelve month picture that totals US$17.7b in revenue, Basic EPS of US$2.22 and net income of US$752m. Over recent quarters, reported revenue has moved from US$4.0b in Q4 2024 to US$4.6b in Q4 2025, while quarterly Basic EPS has ranged from US$1.16 in Q4 2024 to US$0.55 most recently, setting up a results season where investors are weighing...
NasdaqCM:ENGN
NasdaqCM:ENGNBiotechs

enGene Therapeutics (ENGN) Is Down 80.6% After Mixed Phase 2 Bladder Cancer Data Update - What's Changed

Earlier this week, enGene Therapeutics reported interim Phase 2 LEGEND trial results for its bladder cancer gene therapy detalimogene voraplasmid, revealing a 54% complete response rate but weaker 12‑month durability than previously expected, alongside generally manageable side effects and low disease progression. The mixed efficacy profile has triggered analyst downgrades and shareholder-rights investigations, highlighting how a single data update can rapidly reshape perceptions of a...
NYSE:PL
NYSE:PLProfessional Services

Has Planet Labs (PL) Rallied Too Far After 9x One Year Share Price Surge

If you are wondering whether Planet Labs PBC at around US$35.24 is priced attractively or already baking in big expectations, it helps to step back and look at how the stock has been behaving and what that might imply about value. The share price is around US$35.24, with a 4.7% decline over the last week, roughly flat at 0.2% over the past month, a 72.7% gain year to date, and a very large rise over the past year that is close to 9x, as well as very strong multi year returns. These moves...
NYSE:NI
NYSE:NIIntegrated Utilities

NiSource Data Center Deals With Amazon And Alphabet Reframe Growth Story

NiSource (NYSE:NI) announced new and expanded partnerships with Amazon and Alphabet that are expected to support $1.4 billion in customer savings over 15 years. Alongside these partnerships, the company updated its long term adjusted EPS growth outlook to a range of 9% to 10% through 2033. For investors watching utilities, NiSource stands out with a current share price of $47.02 and a 5 year return of 115.2%. The stock has also returned 21.9% over the past year and 83.7% over 3 years,...
NasdaqGS:COLM
NasdaqGS:COLMLuxury

Geopolitical Freight Shock Puts Columbia Sportswear Margin Outlook Under Scrutiny

Geopolitical tensions and higher oil prices are pushing up ocean freight costs for Columbia Sportswear, raising questions about future gross margins. Renewed U.S. Iran frictions are contributing to more expensive international shipping, which could affect sourcing and distribution for Columbia's global business. These supply chain pressures come as investors focus on how apparel companies handle external cost shocks alongside consumer demand trends. Columbia Sportswear (NasdaqGS:COLM) is...
NYSE:PRMB
NYSE:PRMBBeverage

Is Primo Brands (PRMB) Pricing Misaligned After Recent Share Price Recovery?

This article examines whether Primo Brands, trading at around US$22.24, currently represents value or risk by exploring what the share price might be implying. The stock has returned 9.1% over the last 7 days, 21.3% over the last 30 days and 37.4% year to date, while the 1 year return reflects a 29.8% decline and the 3 and 5 year returns are 69.8% and 48.4% respectively. Recent market interest in Primo Brands appears tied to broader investor attention on beverage companies listed in the US...
NasdaqGM:IRON
NasdaqGM:IRONBiotechs

A Look At Disc Medicine (IRON) Valuation As Key APOLLO Phase 3 And Pipeline Milestones Progress

Why Disc Medicine’s latest trial milestones matter for investors Disc Medicine (IRON) has moved its pipeline forward by completing enrollment in the pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria, while also preparing new data readouts across other hematology programs. See our latest analysis for Disc Medicine. The latest trial milestones arrive after a mixed stretch in the market, with the share price at US$67.53 showing a 1-year total shareholder return of...
NasdaqGS:GH
NasdaqGS:GHHealthcare

Guardant Health (GH) Earnings Spotlight Revenue Growth Versus Persistent Losses Challenges Premium Valuation Narratives

Guardant Health (GH) has just posted its FY 2025 numbers with Q4 revenue of US$281.3 million, a basic EPS loss of US$1.00 and net income loss of US$128.5 million, set against a trailing twelve month revenue base of US$982.0 million and a TTM EPS loss of US$3.32. Over recent quarters the company has seen revenue move from US$201.8 million in Q4 FY 2024 to US$281.3 million in Q4 FY 2025. Quarterly basic EPS losses have ranged between US$0.74 and US$1.00, and TTM net income losses have remained...
NasdaqGS:ECPG
NasdaqGS:ECPGConsumer Finance

Encore Capital Charter Vote Tests Governance And Officer Accountability Balances

Encore Capital Group (NasdaqGS:ECPG) is asking shareholders to approve an amendment to its corporate charter. The change would exculpate company officers from personal liability for monetary damages tied to breaches of the duty of care. The proposal is scheduled for a vote at the upcoming annual shareholder meeting. Encore Capital Group operates in the consumer debt buying and collections space, where regulatory scrutiny, legal risk and reputational considerations tend to be front and...
NasdaqGS:ALKS
NasdaqGS:ALKSBiotechs

Is It Time To Reassess Alkermes (ALKS) After Strong Recent Share Price Gains

If you are wondering whether Alkermes at around US$35.40 still offers value, it helps to step back and look at what the recent share performance might be implying about expectations. The stock has returned 5.0% over the last 7 days, 7.2% over 30 days, 25.3% year to date and 16.5% over the past year. This puts recent pricing in clear focus for anyone weighing upside against risk. Recent coverage has centered on Alkermes’ position in the pharmaceuticals and biotech space and how its pipeline...
NasdaqGS:PRVA
NasdaqGS:PRVAHealthcare

Is Privia Health Group (PRVA) Attractive After Recent Volatility And Conflicting Valuation Signals?

Wondering whether Privia Health Group at around US$23.99 is offering fair value or a potential opportunity? This article breaks down what the current price may be telling you. The stock has been volatile recently, with a 3.5% decline over the last 7 days, a 7.2% gain over the last 30 days, and year to date returns of 2.3% after a 4.3% loss over the past year. Those mixed returns come against a backdrop of ongoing interest in healthcare services companies focused on physician enablement and...
NYSE:MSI
NYSE:MSICommunications

Motorola Solutions (MSI) Earnings Margin Expansion Reinforces Bullish Software And Services Narrative

Motorola Solutions (MSI) closed out FY 2025 with fourth quarter revenue of US$3.4 billion and basic EPS of US$3.90, supported by net income of US$649 million. Trailing 12 month figures show revenue of US$11.7 billion and basic EPS of US$12.93. Over the past year, revenue has moved from US$10.8 billion to US$11.7 billion and basic EPS has gone from US$9.45 to US$12.93, alongside trailing 12 month net income rising from US$1.6 billion to US$2.2 billion. This sets the backdrop for a profit story...